1-8 of 8
Michael Osborn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study

Omali Pitiyarachchi, Madeleine T King, Shane Gangatharan, Michael Osborn, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby N Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Philip McCloud, Peter Button, Leesa Rowley, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, Matthew Greenwood
Journal: Blood
Blood (2024) 144 (Supplement 1): 1445.
https://doi.org/10.1182/blood-2024-209043
Published: 2024
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Deborah L. White, PhD. FFSc(RCPA), Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Cassandra Slader, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P Hughes, MD, MBBS
Journal: Blood
Blood (2011) 118 (21): 1690.
https://doi.org/10.1182/blood.V118.21.1690.1690
Published: 2011
Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2011) 118 (21): 451.
https://doi.org/10.1182/blood.V118.21.451.451
Published: 2011
Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2010) 116 (21): 356.
https://doi.org/10.1182/blood.V116.21.356.356
Published: 2010
Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2010) 116 (21): 209.
https://doi.org/10.1182/blood.V116.21.209.209
Published: 2010
Journal Articles

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

Shriram Vaidia Nath, FRCPA, DM, MD, D.Ped, MBBS, Michelle Tamblyn, Dip., Med., Tech, Grad, Cert, Surg, Path, Prep, Susan Telfer, BSc(Hons), Grad, Cert, Surg, Path, Prep, Tony Henwood, JP, MSc, BAppSc, GradDipSysAnalys, CT(ASC), Peter Gilham, Colin Story, MSc, Greg Hodge, PhD, Akash Kalro, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Ram Suppiah, MBBS, FRACP, FRCPA, Heather Tapp, MBBS, FRACP, FRCPA, Ian C Nicholson, PhD, BSc(Hons), BSc, Heddy Zola, PhD, FRCPA, Sarah Moore, B, App, Sci, BSc(Hons), Andrew Zannettino, BSc, PhD, Nick Manton, FRCPA, Tamas Revesz, MD, PhD, FRACP
Journal: Blood
Blood (2010) 116 (21): 2566.
https://doi.org/10.1182/blood.V116.21.2566.2566
Published: 2010
Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2010) 116 (21): 2288.
https://doi.org/10.1182/blood.V116.21.2288.2288
Published: 2010